Table of Contents Table of Contents
Previous Page  246 / 1096 Next Page
Information
Show Menu
Previous Page 246 / 1096 Next Page
Page Background

S233

ESTRO 36

_______________________________________________________________________________________________

response can be quantified and predicted using Tumor

Metabolic Ratio (TMR) matrix obtained during the early

treatment weeks from multiple FDG-PET imaging.

Material and Methods

FDG-PET/CT images of 15 HN cancer patients obtained

pre- and weekly during the treatment were used. TMR was

constructed following voxel-by-voxel deformable image

registration. TMR of each tumor voxel,

v

, was a function

of the pre-treatment SUV and the delivered dose,

d

, such

as TMR(

v

,

d

) = SUV(

v

,

d

)/SUV(

v

, 0). Utilizing all voxel

values of TMR in the controlled tumor group at the last

treatment week, a bounding function between the pre-

treatment SUV and TMR was formed, and applied in early

treatment days for all tumor voxels to model a tumor voxel

control probability (TVCP). At the treatment week

k

, TVCP

of each tumor voxel was constructed based on its pre-

treatment SUV and TMR obtained at the week

k

using the

maximum likelihood estimation on the Poisson TCP model

for all dose levels. The DPF at the week

k

was created

selecting the maximum TVCP at each level of the pre-

treatment SUV and TMR measured at the week

k

. In

addition, 150Gy was used as an upper limit for the target

dose.

Results

TVCP estimated in the early treatment week, i.e. week 2,

had their D

50

=13~65Gy; g

50

= 0.56~1.6 respectively with

respect to TMR = 0.4~1.2; Pre-treatment SUV = 3.5~16.

Figure 1 shows the TVCP estimated using the TMR

measured at the week 2 with different levels of pre-

treatment SUV, as well as TVCP at different weeks, the

week 2 ~ week 4. Large dose will be required to achieve

the same level of tumor control for the same level of TMR

appeared in the later week of treatment. Figure 2 shows

the corresponding DPF for the week 3 TMR, as well as the

prescribed tumor dose distribution for the 3 failures.

Figure

1

Figure 2

Conclusion

DPF can be estimated and constructed adaptively voxel-

by-voxel in human tumor using multiple FDG-PET imaging

obtained during the treatment course. DPF provides a

potential quantitative objective for adaptive DPbN to plan

the best clinical dose, escalate or de-escalate, in human

tumor based on its own radiosensitivity or radioresistance.

OC-0442 Intensity based synthetic CT generation from

standard T2-weighted MR images with three MR

scanners

L. Koivula

1

, L. Wee

2

, J. Dowling

3

, P. Greer

4

, T. Seppälä

1

,

J. Korhonen

1

1

Comprehensive Cancer Center- Helsinki University

Central Hospital, Department of radiation oncolocy,

Helsinki, Finland

2

Danish Colorectal Cancer Center South, Vejle Hospital,

Vejle, Denmark

3

Commonwealth Scientific and Industrial Research

Organisation CSIRO, CSIRO ICT Centre, Brisbane,

Australia

4

Calvary Mater Newcastle Hospital, Radiation Oncology,

Newcastle, Australia

Purpose or Objective

Recent studies have shown feasibility t o conduct the

entire radiotherapy treatment planning workflow relying

solely on magnetic resonance imaging (M RI). Yet, few

hospitals have implemented the MRI-only workflow into

clinical routine. One limiting issue is the requisite

construction of a synthetic computed tomography (sCT)

image. The majority of published sCT generation methods

necessitate inclusion of extra sequences into the

simulation imaging protocol. This study aims to develop an

intensity-based sCT generation method that relies only on

image data from standard T2-weighted sequence. The

work includes images derived from three different

manufacturers’ MR scanners. The primary target group

was prostate, for which T2-weighted images are already

used as standard target delineation images.

Material and Methods

The study utilized a total of 30 standard T2-weighted

images acquired for prostate target delineation in three

different clinics. The imaging was conducted with MR

scanners (GE Optima 1.5T, Philips Ingenia 1.5T, and

Siemens Skyra 3.0T) of each participating clinic by using

their typical clinical settings. Intensity value variations of

the obtained images were studied locally, and compared

to corresponding Hounsfield units (HUs) of a standard CT

image. The data of 21 of the 30 prostate patients was used

to generate conversion models for bony and soft tissues to

transform the MR image into sCT. The models were

optimized separately for the images obtained by each MR

platform. The sCT generation was tested for 9 of the 30